Value based pricing for NHS drugs: An opportunity not to be missed?

BMJ

Volumn 336, Issue 7638, 2008, Pages 251-254

  Claxton, Karl ^a   Lindsay, Andrew Briggs ^b   Buxton, Martin J ^c   Culyer, Anthony J ^a,d   McCabe, Christopher ^e   Walker, Simon ^a   Sculpher, Mark J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EVIDENCE BASED MEDICINE; FUNDING; GOVERNMENT; HEALTH SURVEY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; UNITED KINGDOM;

EID: 39149109948     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39434.500185.25     Document Type: Short Survey

References (22)

1. Office of Fair Trading. The pharmaceutical price regulation scheme. An OFT market study. London: Office of Fair Trading, 2007. www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf
2. Collier J. The pharmaceutical price regulation scheme. BMJ 2007;334:435-6.
3. Department of Business Enterprise and Regulatory Reform. Interim government response to Office of Fair Trading (OFT) market study on PPRS. London: Department of Business Enterprise and Regulatory Reform, 2007. (URN 07/1247.) www.berr.gov.uk/files/file40756.pdf
4. National Institute for Health and Clinical Excellence. First report of the health committee 2007-2008. London: Stationery Office, 2008. (HC27-I.)
5. Collier J. Parliamentary review asks NICE to do better still. BMJ 2008;336:56-7.
6. Culyer AJ, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Pol 2007;12:56-8.
7. Martin S, Rice N, Smith PC. The link between health care spending and health outcomes: evidence from English programme budgeting data. University of York: Centre for Health Economics, 2007. (Research Paper 24.)
8. National Institute for Health and Clinical Excellence. Clinical and Public Health Directorate progress report. London: NICE, 2007. www.nice.org.uk/page.aspx?o=399398
9. Claxton K. OFT, VBP: QED? Health Econ 2007;16:545-58.
10. A new prescription. Economist 2007;382:68-9.
11. Boseley S. Drugs price fixing scheme costs health service millions, says OFT. Guardian 2007 February 20.
12. Opinion. OFT's bitter pill will just have to be swallowed, Business Commentary. Times 2007 February 21.
13. Leader. In search of a perfect price for drugs. Financial Times 2007 February 21.
14. Brown C. Drug firms accused of 'ripping off' the NHS. Independent 2007 February 21.
15. Stagg C. Can we afford medical progress? New Statesman 2007 June 11.
16. Evans R, Boseley S. Drug firms' lobby tactics revealed. Guardian 2006 September 28.
17. Boseley S. Open up NHS to our drug firms, White House demands. Guardian 2006 November 14.
18. Griffin S, Claxton K, Palmer S, Sculpher MJ. Dangerous omissions: the consequences of ignoring decision uncertainty. Med Decison Making 2007;27:E8.
19. Claxton K, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006;24:1055-68.
20. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004.
21. Buxton MJ, Akehurst R. How NICE is the UK's fast-track system? Scrip Magazine 2006;152:24-5.
22. Cooksey D. A review of UK health research funding. London: Stationery Office, 2006.